Ann: Opthea Signs Cell Line Commercial License Ag, page-5

re: Ann: Opthea Signs Cell Line Commercial Li... They have plenty else going on as well

Could be time for that chart to turn upside down

For a biotech, pretty damn cheap -

$10 million cap
$9 million in cash plus 2.2 million in listed shares

Control over 400 patents

Several therapeutic development partnering events expected during 2014.

Commercial partnerships already in place with:

- Eli Lilly: Developing IMC-3C5, a cancer treatment, with ImClone, a subsidiary of Eli Lilly (Eli Lilly makes Prozac, amongst other things)

- Merck Millipore

- Healthscope: Developed CupGuide, a molecular diagnostic for cancers of unknown primary origin, already on sale with orders and revenue to ramp up this year following oncologist education

- Perkin Elmer
- Bio-rad
- Ark Therapeutics

Ongoing royalty streams of $550k pa increasing to $1 million pa from this year


Collaborations with:

– Harvard
– UCLA
– CSIRO
– Ludwig Institute of Cancer Research
– University of Helsinki
– Peter Maccallum Cancer Institute
– Centre for Eye Research Australia

New licensing deal announced this morning with Selexis

Cancer inhibition technology/methodology I can actually understand:

Charts look just about ready for a reversal-

long term chart looks floored
short term turning up with good OBV

Titus you must be a Peter Lynch fan as well!